Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer.
Durski, J. M., Srinivas, S., & Segall, G. (2000). Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T, 3(3), 97–105.

High-dose chemotherapy in poor-risk germ-cell tumors
Srinivas, S. (2000). High-dose chemotherapy in poor-risk germ-cell tumors. ONCOLOGY-NEW YORK, 14(10), 1419–1423.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer
Kiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. UROLOGY, 57(1), 127–32.

Positron emission tomography in the initial staging of esophageal cancer
Wren, S. M., Stijns, P., & Srinivas, S. (2002). Positron emission tomography in the initial staging of esophageal cancer. ARCHIVES OF SURGERY, 137(9), 1001–6.

Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily
Murphy, J. C., Srinivas, S., & Terris, M. K. (2004). Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. JOURNAL OF ANDROLOGY, 25(4), 630–634.

Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis
Morgan, K., Srinivas, S., & Freiha, F. S. (2004). Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. UROLOGY, 64(4).

A nonplatinum combination in metastatic transitional cell carcinoma
Srinivas, S., & Guardino, A. E. (2005). A nonplatinum combination in metastatic transitional cell carcinoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 28(2), 114–18.

A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma
Srinivas, S., & Guardino, A. E. (2005). A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU INTERNATIONAL, 96(4), 536–39.

Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.
Badger, J., Kang, S., Uzieblo, A., & Srinivas, S. (2005). Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. Journal of Clinical Oncology , 23(28), 7224–25.

Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer
Srinivas, S., Krishnan, A. V., Colocci, N., & Feldman, D. (2006). Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. UROLOGY, 67(5), 1001–6.

Nonplatinum therapy in advanced bladder cancer
Srinivas, S., & Colocci, N. (2006). Nonplatinum therapy in advanced bladder cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 6(6), 887–94.

Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
King, C. R., McNeal, J. E., Gill, H., Brooks, J. D., Srinivas, S., & Presti, J. C. (2006). Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. UROLOGY, 67(6), 1229–34.

Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy
Liu, I. J., Lai, Y.-H., Espiritu, J. I., Segall, G. M., Srinivas, S., Nino-Murcia, M., & Terris, M. K. (2006). Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. UROLOGIA INTERNATIONALIS, 77(1), 69–75.

Bone related events in high risk prostate cancer
Srinivas, S., & Colocci, N. (2006). Bone related events in high risk prostate cancer. JOURNAL OF UROLOGY, 176(6), S50–S54.

Prostate cancer. Clinical practice guidelines in oncology.
Mohler, J., Babaian, R. J., Bahnson, R. R., Boston, B., D'Amico, A., Eastham, J. A., … Walsh, P. C. (2007). Prostate cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 5(7), 650–683.

Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer
Feldman, D., Krishnan, A., Moreno, J., Swami, S., Peehl, D. M., & Srinivas, S. (2007). Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. NUTRITION REVIEWS, 65(8), S113–S115.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., … McDermott, D. (2007). Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(29), 4536–41.

Acute pancreatitis associated with sorafenib
Li, M., & Srinivas, S. (2007). Acute pancreatitis associated with sorafenib. SOUTHERN MEDICAL JOURNAL, 100(9), 909–11.

Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma
Harshman, L. C., & Srinivas, S. (2007). Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. EXPERT REVIEW OF ANTICANCER THERAPY, 7(12), 1749–61.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613–1618.

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
Jonasch, E., Stadler, W. M., Bukowski, R. M., Hayes, T. G., Varadhachary, A., Malik, R., … Srinivas, S. (2008). Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. CANCER, 113(1), 72–77.

Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer
Harshman, L., & Srinivas, S. (2008). Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. ONKOLOGIE, 31(8-9), 432–33.

The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer
Harshman, L. C., Li, M., & Srinivas, S. (2008). The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 31(5), 417–23.

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib
Harshman, L. C., Srinivas, S., Kamaya, A., & Chung, B. I. (2009). Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. NATURE REVIEWS UROLOGY, 6(6), 338–43.

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma
Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., & Srinivas, S. (2009). Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. CANCER INVESTIGATION, 27(8), 851–56.

A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma
Srinivas, S., & Harshman, L. C. (2009). A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma. CHEMOTHERAPY, 55(5), 321–26.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., Mulder, S. F., … Vogelzang, N. J. (2009). Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 27(25), 4068–75.

A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer
Srinivas, S., & Feldman, D. (2009). A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. ANTICANCER RESEARCH, 29(9), 3605–10.

Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.
Krishnan, A. V., Srinivas, S., & Feldman, D. (2009). Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermato-Endocrinology, 1(1), 7–11.

NCCN clinical practice guidelines in oncology: prostate cancer.
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., … Walsh, P. C. (2010). NCCN clinical practice guidelines in oncology: prostate cancer. Journal of the National Comprehensive Cancer Network , 8(2), 162–200.

Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
Dreicer, R., Garcia, J., Hussain, M., Rini, B., Vogelzang, N., Srinivas, S., … Raghavan, D. (2011). Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. INVESTIGATIONAL NEW DRUGS, 29(6), 1441–48.

Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients
Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., Allen, G. I., & Srinivas, S. (2010). Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU INTERNATIONAL, 106(11), 1805–11.

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
Pili, R., Rosenthal, M. A., Mainwaring, P. N., van Hazel, G., Srinivas, S., Dreicer, R., … Clingan, P. (2010). Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC. CLINICAL CANCER RESEARCH, 16(10), 2906–14.

The bevacizumab experience in advanced renal cell carcinoma
Harshman, L. C., & Srinivas, S. (2010). The bevacizumab experience in advanced renal cell carcinoma. ONCOTARGETS AND THERAPY, 3, 179–89.

Pyoderma Gangrenosum With the Use of Sunitinib
Nadauld, L. D., Miller, M. B., & Srinivas, S. (2011). Pyoderma Gangrenosum With the Use of Sunitinib. JOURNAL OF CLINICAL ONCOLOGY, 29(10), E266–E267.

Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)
Harshman, L. C., Yu, R. J., Allen, G. I., Srinivas, S., Gill, H. S., & Chung, B. I. (2013). Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 31(3), 379–85.

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., Bubley, G., … Ross, R. W. (2011). Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer. UROLOGY, 78(3), 626–30.

Toxicities of targeted agents in advanced renal cell carcinoma.
Patel, P., & Srinivas, S. (2011). Toxicities of targeted agents in advanced renal cell carcinoma. Current Clinical Pharmacology, 6(3), 181–88.

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
Harshman, L. C., Xie, W., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Wood, L., … Choueiri, T. K. (2012). Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. LANCET ONCOLOGY, 13(9), 927–35.

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A. V., … Shead, D. A. (2012). Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(9), 1081–87.

Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance
Patel, P., Balise, R., & Srinivas, S. (2012). Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance. ONKOLOGIE, 35(10), 588–91.

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Ryan, C. J., Rosenthal, M., Ng, S., Alumkal, J., Picus, J., Gravis, G., … Gerritsen, W. R. (2013). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. CLINICAL CANCER RESEARCH, 19(1), 215–24.

mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer
Cann, G. M., Gulzar, Z. G., Cooper, S., Li, R., Luo, S., Tat, M., … Talasaz, A. A. H. (2012). mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer. PLOS ONE, 7(11).

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., … Hussain, M. (2013). Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. JOURNAL OF CLINICAL ONCOLOGY, 31(4), 412–19.

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., … Srinivasan, R. (2013). Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 31(2), 181–86.

A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma.
Harshman, L. C., Barbeau, S., McMillian, A., & Srinivas, S. (2013). A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 11(2), 100–106.

THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL
Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., & Srinivas, S. (1993). THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL. ANNALS OF INTERNAL MEDICINE, 119(9), 874–881.

INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES
Reilly, B. M., Raschke, R., Srinivas, S., & Nieman, T. (1993). INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES. JOURNAL OF GENERAL INTERNAL MEDICINE, 8(10), 536–542.

THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER
Small, E. J., & Srinivas, S. (1995). THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER. CANCER, 76(8), 1428–1434.

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer
Small, E. J., Srinivas, S., Egan, B., McMillan, A., & Rearden, T. P. (1996). Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 14(5), 1617–1625.

Methotrexate tolerance in patients with ileal conduits and continent diversions
Srinivas, S., Mahalati, K., & Freiha, F. S. (1998). Methotrexate tolerance in patients with ileal conduits and continent diversions. CANCER, 82(6), 1134–36.

Node Positive Bladder Cancer
Node Positive Bladder Cancer. (2005). Arab J Urology, 3.

Utility of bone scan post primary therapy in prostate cancer
Utility of bone scan post primary therapy in prostate cancer. (2002). UroOncology, 2.

Management choices in stage I non-seminomatous Germ Cell Tumor
Management choices in stage I non-seminomatous Germ Cell Tumor. (2001). UroOncology, 1.

High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience.
High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience. (2009). Bone Marrow Transplant, 43(7).

Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer
Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer. (2009). Dermato Endocrinolgy, 1.

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. (2011). J Natl Compr Canc Network, 9.

Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer
Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer. (2010). Open Prostate Cancer Journal, 3.

NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R. N., … Van Poznak, C. H. (2009). NCCN Task Force Report: Bone Health in Cancer Care. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7, S1–S32.

Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies.
Srinivas, S., & Guardino, A. E. (2004). Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 425S–425S.

A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)
Ross, R. W., Srinivasan, R., Vaishampayan, U., Bukowski, R., Rosenberg, J., Eisenberg, P., … Keer, H. N. (2007). A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). MOLECULAR CANCER THERAPEUTICS, 6(12), 3511S–3511S.

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma
Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., & Srinivas, S. (2008). Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. BLOOD. SAN FRANCISCO,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.

Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC)
Harshman, L. C., Kuo, C. J., & Srinivas, S. (2008). Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC). JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.
Zhong, L., Srinivas, S., Pon, V., Nicole Nguyen, N., Frear, M., Kwan, S., … Wilson, L. (2012). Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age
Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., ALLEN, G. I., Tibshirani, R., & Srinivas, S. (2009). Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

RRM1 expression in muscle invasive, locally advanced urothelial cancer is associated with survival in younger patients
Harshman, L., Bepler, G., Zheng, Z., Higgins, J., Allen, G., & Srinivas, S. (2009). RRM1 expression in muscle invasive, locally advanced urothelial cancer is associated with survival in younger patients. EJC SUPPLEMENTS, 7(4), 19–19.

Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma
Srinivas, S., Kabbinavar, F. F., Hauke, R. J., Esteves, B., Cotreau, M. M., Strahs, A. L., & Fishman, M. N. (2012). Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma. Presented at the 10th International Kidney Cancer Symposium, CHICAGO,IL: WILEY-BLACKWELL.

Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy.
Harshman, L. C., Bepler, G., Quinn, D. I., McKenney, J., Hawes, D., Simon, N., … Dorff, T. B. (2012). Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.
Hall, P. S., Witteles, R., Srinivas, S., & Harshman, L. C. (2012). Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
Zhong, L., Pon, V., Srinivas, S., Nguyen, N., Frear, M., Kwon, S., … Wilson, L. (2013). Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis. PLOS ONE, 8(5).

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
Kroeger, N., Xie, W., Lee, J.-L., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., … Heng, D. Y. C. (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. CANCER, 119(16), 2999–3006.

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Dreicer, R., Garcia, J., Rini, B., Vogelzang, N., Srinivas, S., Somer, B., … Raghavan, D. (2013). A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. INVESTIGATIONAL NEW DRUGS, 31(4), 1044–50.

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
Fishman, M. N., Srinivas, S., Hauke, R. J., Amato, R. J., Esteves, B., Cotreau, M. M., … Kabbinavar, F. F. (2013). Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. EUROPEAN JOURNAL OF CANCER, 49(13), 2841–2850.

TEMPORAL TRENDS IN UTILIZATION OF CYTOREDUCTIVE NEPHRECTOMY AND PATIENT SURVIVAL IN THE TARGETED THERAPY ERA
Conti, S. L., Hagedorn, J., Chung, B. I., Srinivas, S., & Leppert, J. (2013). TEMPORAL TRENDS IN UTILIZATION OF CYTOREDUCTIVE NEPHRECTOMY AND PATIENT SURVIVAL IN THE TARGETED THERAPY ERA. JOURNAL OF UROLOGY, 189(4), E753–E753.

Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., … Leppert, J. T. (2014). Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. International Journal of Cancer. Journal International Du Cancer, 134(9), 2245–52.

Utilization of renal mass biopsy in patients with renal cell carcinoma.
Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., Chertow, G. M., … Saigal, C. S. (2014). Utilization of renal mass biopsy in patients with renal cell carcinoma. Urology, 83(4), 774–80.

Reply.
Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., Srinivas, S., … Saigal, C. S. (2014). Reply. Urology, 83(4), 779–80.

Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., … Ho, M. (2013). Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(12), 1471–79.

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Heng, D. Y. C., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., Pal, S. K., … Wood, L. A. (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology , 25(1), 149–54.

Prostate cancer, version 1.2014.
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., … Ho, M. (2013). Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network , 11(12), 1471–1479.

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., Bjarnason, G. A., … Choueiri, T. K. (2014). Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. European Urology, 65(3), 577–84.

The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the international metastatic renal cell cancer database consortium.
Schutz, F. A. B., Xie, W., Donskov, F., Sircar, M., McDermott, D. F., Rini, B. I., … Choueiri, T. K. (2014). The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the international metastatic renal cell cancer database consortium. European Urology, 65(4), 723–30.

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients.
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC. Heart Failure, 1(1), 72–78.

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells
Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., … Leppert, J. T. (2014). KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. INTERNATIONAL JOURNAL OF CANCER, 134(9), 2245–52.

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Ko, J. J., Choueiri, T. K., Rini, B. I., Lee, J., Kroeger, N., Srinivas, S., … Heng, D. Y. C. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer, 110(8), 1917–22.

Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy
Kroeger, N., Choueiri, T. K., Lee, J.-L., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., … Heng, D. Y. C. (2014). Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. EUROPEAN UROLOGY, 65(6), 1086–92.

Prostate cancer, version 2.2014.
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., … Ho, M. (2014). Prostate cancer, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(5), 686–718.

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed, N., Lee, J.-L., Srinivas, S., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., … Heng, D. Y. C. (2014). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 12(4), e127–31.

First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium
Harshman, L. C., Kroeger, N., Rha, S. Y., Donskov, F., Wood, L., Tantravahi, S. K., … Choueiri, T. K. (2014). First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. CLINICAL GENITOURINARY CANCER, 12(5), 335–40.

Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Heng, D. Y. C., Wells, J. C., Rini, B. I., Beuselinck, B., Lee, J.-L., Knox, J. J., … Choueiri, T. K. (2014). Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. EUROPEAN UROLOGY, 66(4), 704–10.

Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma Reply
Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., Srinivas, S., … Saigal, C. S. (2014). Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma Reply. UROLOGY, 83(4), 779–80.

Utilization of renal mass biopsy in patients with renal cell carcinoma
Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., Chertow, G. M., … Saigal, C. S. (2013). Utilization of renal mass biopsy in patients with renal cell carcinoma. Presented at the 12th International Kidney Cancer Symposium, CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL: WILEY-BLACKWELL.

Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era
Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., … Leppert, J. T. (2013). Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Presented at the 12th International Kidney Cancer Symposium, CHICAGO,IL,IL,IL,IL,IL,IL,IL,IL,IL: WILEY-BLACKWELL.

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., … Heng, D. Y. C. (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. The Lancet. Oncology, 16(3), 293–300.

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium.
Kyriakopoulos, C. E., Chittoria, N., Choueiri, T. K., Kroeger, N., Lee, J.-L., Srinivas, S., … Rini, B. I. (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clinical Genitourinary Cancer, 13(2), e79–85.

A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma
Hussain, M., Daignault, S., Agarwal, N., Grivas, P. D., Siefker-Radtke, A. O., Puzanov, I., … Smith, D. C. (2014). A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma. CANCER, 120(17), 2684–93.

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial
Harrop, R., Chu, F., Gabrail, N., Srinivas, S., Blount, D., & Ferrari, A. (2013). Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(9), 1511–20.

Second-Line Therapies in Metastatic Urothelial Carcinoma
Narayanan, S., Harshman, L. C., & Srinivas, S. (2015). Second-Line Therapies in Metastatic Urothelial Carcinoma. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 29(2), 341-?

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., … Srinivas, S. (2011). NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9, S1–S29.

NCCN Task Force Report: Bone Health In Cancer Care.
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., … Van Poznak, C. H. (2013). NCCN Task Force Report: Bone Health In Cancer Care. Journal of the National Comprehensive Cancer Network , 11, S1–50.

NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., … Van Poznak, C. H. (2013). NCCN Task Force Report: Bone Health in Cancer Care. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11, S1–S50.

Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
Kroeger, N., Pantuck, A. J., Wells, J. C., Lawrence, N., Broom, R., Kim, J. J., … Heng, D. Y. (2015). Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. EUROPEAN UROLOGY, 68(3), 506–15.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger, N., Pantuck, A. J., Wells, J. C., Lawrence, N., Broom, R., Kim, J. J., … Heng, D. Y. (2015). Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. European Urology, 68(3), 506–515.

Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.
Narayanan, S., Srinivas, S., & Feldman, D. (2016). Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nature Reviews. Urology, 13(1), 47–60.

Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy
Narayanan, S., Srinivas, S., & Feldman, D. (2016). Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. NATURE REVIEWS UROLOGY, 13(1), 47–60.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., … Sharma, P. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE, 373(19), 1803–13.

Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., D'Amico, A. V., Davis, B. J., Eastham, J. A., … Freedman-Cass, D. A. (2016). Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(1), 19–30.

Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
Barbosa, P. V., Thomas, I.-C., Srinivas, S., Buyyounouski, M. K., Chung, B. I., Chertow, G. M., … Leppert, J. T. (2016). Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable? EUROPEAN UROLOGY, 70(2), 227–30.

Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., & Kwong, B. Y. (2016). Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. Journal of Cutaneous Pathology, 43(4), 339–46.

Disparities in Adolescent and Young Adult Survival After Testicular Cancer Vary by Histologic Subtype: A Population-Based Study in California 1988-2010.
DeRouen, M. C., Mujahid, M., Srinivas, S., & Keegan, T. H. M. (2016). Disparities in Adolescent and Young Adult Survival After Testicular Cancer Vary by Histologic Subtype: A Population-Based Study in California 1988-2010. Journal of Adolescent and Young Adult Oncology, 5(1), 31–40.

New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson, L., Tang, J., Zhong, L., Balani, G., Gipson, G., Xiang, P., … Srinivas, S. (2014). New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 20(6), 417–25.

Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model
Salah, S., Lee, J.-L., Rozzi, A., Kitamura, H., Matsumoto, K., Srinivas, S., … Maakoseh, M. (2016). Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. CLINICAL GENITOURINARY CANCER, 14(3), 255–60.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., … Dreicer, R. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. LANCET, 387(10031), 1909–20.

Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma
Minamimoto, R., Barkhodari, A., Harshman, L., Srinivas, S., & Quon, A. (2016). Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma. PLOS ONE, 11(4).

Case 3. Photo therapy recall with gemcitabine following ultraviolet B treatment
Badger, J., Uzieblo, A., Srinivas, S., & Kang, S. W. (2005). Case 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. JOURNAL OF CLINICAL ONCOLOGY, 23(28), 7224–25.

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC-HEART FAILURE, 1(1), 72–78.

Prostate Cancer
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., … Walsh, P. C. (2010). Prostate Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(2), 162–200.

Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Narayanan, S., Lam, A., Vaishampayan, U., Harshman, L., Fan, A., Pachynski, R., … Srinivas, S. (2016). Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. Clinical Genitourinary Cancer, 14(5), 432–37.

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations
Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., … Choueiri, T. K. (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. JOURNAL OF CLINICAL ONCOLOGY, 34(30), 3655-?

The effect of information on preferences for treatments of metastatic renal cell carcinoma.
Mansfield, C., Srinivas, S., Chen, C., Hauber, A. B., Hariharan, S., Matczak, E., & Sandin, R. (2016). The effect of information on preferences for treatments of metastatic renal cell carcinoma. Current Medical Research and Opinion, 32(11), 1827–38.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi, A., Sonpavde, G., Lo Vullo, S., Giardiello, D., Bamias, A., Crabb, S. J., … Mariani, L. (2016). Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
Necchi, A., Sonpavde, G., Lo Vullo, S., Giardiello, D., Bamias, A., Crabb, S. J., … Mariani, L. (2017). Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). EUROPEAN UROLOGY, 71(2), 281–89.

New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson, L., Tang, J., Zhong, L., Balani, G., Gipson, G., Xiang, P., … Srinivas, S. (2014). New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 20(6), 417–25.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.
de Velasco, G., Xie, W., Donskov, F., Albiges, L., Beuselinck, B., Srinivas, S., … Choueiri, T. K. (2017). Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer.

Incorporating VEGF-targeted therapy in advanced urothelial cancer
Narayanan, S., & Srinivas, S. (2017). Incorporating VEGF-targeted therapy in advanced urothelial cancer. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 9(1), 33–45.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., … Bajorin, D. F. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. LANCET, 389(10064), 67–76.

Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Wells, J. C., Stukalin, I., Norton, C., Srinivas, S., Lee, J. L., Donskov, F., … Heng, D. Y. C. (2017). Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. EUROPEAN UROLOGY, 71(2), 204–9.

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., … Motzer, R. J. (2017). CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology.

Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.
Salah, S., Lee, J.-L., Rozzi, A., Kitamura, H., Matsumoto, K., Vis, D. J., … Lewin, J. (2016). Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies. Clinical Genitourinary Cancer.

Characterizing the outcomes of metastatic papillary renal cell carcinoma
Wells, J. C., Donskov, F., Fraccon, A. P., Pasini, F., Bjarnason, G. A., Beuselinck, B., … Heng, D. Y. C. (2017). Characterizing the outcomes of metastatic papillary renal cell carcinoma. CANCER MEDICINE, 6(5), 902–9.

Consolidative Radiotherapy in Metastatic Urothelial Cancer.
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., & Srinivas, S. (2017). Consolidative Radiotherapy in Metastatic Urothelial Cancer. Clinical Genitourinary Cancer.

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category
Davis, I. D., Xie, W., Pezaro, C., Donskov, F., Wells, J. C., Agarwal, N., … Heng, D. Y. C. (2017). Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. EUROPEAN UROLOGY, 71(6), 970–78.

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis, I. D., Xie, W., Pezaro, C., Donskov, F., Wells, J. C., Agarwal, N., … Heng, D. Y. C. (2017). Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 71(6), 970–78.

Consolidative radiotherapy in metastatic urothelial cancer (MUC)
Srinivas, S., Narayanan, S., Fan, A. C., Hancock, S. L., & Skinner, E. C. (2016). Consolidative radiotherapy in metastatic urothelial cancer (MUC). JOURNAL OF CLINICAL ONCOLOGY, 34(2).

Combined NaF/FDG PET/CT evaluation of prostate cancer patients
Iagaru, A., Mosci, C., Keu, K. V., Mittra, E., Hancock, S., Pachynski, R., … Gambhir, S. (2014). Combined NaF/FDG PET/CT evaluation of prostate cancer patients. JOURNAL OF NUCLEAR MEDICINE, 55.

NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC
Leppert, J., Fan, A., Liliental, J., Xu, L., Thong, A., Yost, C., … Felsher, D. (2013). NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC. JOURNAL OF UROLOGY, 189(4), E246–E247.

Real world chart review study of adverse events of special interest (AESI) Management in patients taking tyrosine kinase inhibitors (TKis) to treat metastatic renal cell carcinoma (mRCC)
Srinivas, S., Stein, D., Teltsch, D., Tao, S., Chen, C., Cisar, L., & Ramaswamy, K. (2015). Real world chart review study of adverse events of special interest (AESI) Management in patients taking tyrosine kinase inhibitors (TKis) to treat metastatic renal cell carcinoma (mRCC). BJU INTERNATIONAL. WILEY-BLACKWELL.

Exploring the effect of medication features in renal cell carcinoma: A patient preference study
Srinivas, S., Mansfield, C., Sandin, R., Hauber, A. B., Hariharan, S., Matczak, E., … Chen, C. (2015). Exploring the effect of medication features in renal cell carcinoma: A patient preference study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (vol 72, pg 962, 2017)
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., … Motzer, R. J. (2018). CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (vol 72, pg 962, 2017). EUROPEAN UROLOGY, 73(4), E116–E118.

Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors
Kunder, C., Imae, Y., Srinivas, S., & Fan, A. C. (2018). Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors. MODERN PATHOLOGY, 31, 703.

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm
Tandstad, T., Kollmannsberger, C. K., Roth, B. J., Jeldres, C., Gillessen, S., Fizazi, K., … Nichols, C. R. (2017). Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. JOURNAL OF CLINICAL ONCOLOGY, 35(31), 3525-+.

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
Dietrich, B., & Srinivas, S. (2018). Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. RESEARCH AND REPORTS IN UROLOGY, 10, 7–16.

Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Heng, D. Y. C., Rini, B. I., Beuselinck, B., Lee, J.-L., Knox, J. J., Bjarnason, G. A., … Choueiri, T. K. (2014). Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT)
Templeton, A. J., Heng, D. Y. C., Choueiri, T. K., McDermott, D. F., Fay, A. P., Srinivas, S., … Knox, J. J. (2014). Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., … Hahn, N. M. (2017). Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study. JAMA ONCOLOGY, 3(9), e172411.

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Morales, J. M. R., Wells, J. C., Donskov, F., Bjarnason, G. A., Lee, J.-L., Knox, J. J., … Heng, D. Y. C. (2016). First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 34(2).

Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.
Davis, I. D., Xie, W., Pezaro, C. J., Donskov, F., Wells, C., Agarwal, N., … Heng, D. Y. C. (2016). Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. JOURNAL OF CLINICAL ONCOLOGY, 34(2).

Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).
de Velasco, G., Xie, W., Donskov, F., Albiges, L., Beuselinck, B., Srinivas, S., … Choueiri, T. K. (2016). Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). JOURNAL OF CLINICAL ONCOLOGY, 34(2).

First line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium
Morales, J. M. R., Wells, J. C., Donskov, F., Bjarnason, G. A., Lee, J. L., Knox, J. J., … Heng, D. Y. C. (2015). First line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. BJU INTERNATIONAL, 116, 20.

The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium
Albiges, L., Xie, W., Lee, J.-L., Rini, B. I., Srinivas, S., Bjarnason, G. A., … Choueiri, T. K. (2014). The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
Heng, D. Y. C., Stukalin, I., Wells, C., Donskov, F., Rini, B. I., Lee, J.-L., … Choueiri, T. K. (2015). Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
Heng, D. Y. C., Wells, C., Donskov, F., Rini, B. I., Lee, J.-L., Bjarnason, G. A., … Choueiri, T. K. (2015). Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium. JOURNAL OF CLINICAL ONCOLOGY, 33(7).

Second-line chemotherapy for metastatic urothelial cell carcinoma: Pooled analysis and construction of a prognostic model.
Salah, S., Lee, J.-L., Rozzi, A., Kitamura, H., Matsumoto, K., Srinivas, S., … Maakoseh, M. (2015). Second-line chemotherapy for metastatic urothelial cell carcinoma: Pooled analysis and construction of a prognostic model. JOURNAL OF CLINICAL ONCOLOGY, 33(7).

First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC)
Heng, D. Y. C., Rini, B. I., Lee, J.-L., Kroeger, N., Srinivas, S., Harshman, L. C., … Choueiri, T. K. (2013). First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy
Kroeger, N., Lee, J.-L., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Vaishamayan, U. N., … Heng, D. Y. C. (2013). Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium
Chittoria, N., Zhu, H., Choueiri, T. K., Kroeger, N., Lee, J.-L., Srinivas, S., … Heng, D. Y. C. (2013). Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC)
McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., Bjarnason, G. A., … Choueiri, T. K. (2013). Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 31(6).

Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes
Kroeger, N., Xie, W., Lee, J.-L., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., … Heng, D. Y. C. (2013). Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes. JOURNAL OF CLINICAL ONCOLOGY, 31(6).

Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.
Dietrich, B., Siefker-Radtke, A. O., Srinivas, S., & Yu, E. Y. (2018). Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (38), 342–53.

Prognostic features for testicular cancers (TCs): Can this be gleaned from pathology reports?
Srinivas, S., Eisenberg, M., & Skinner, E. C. (2015). Prognostic features for testicular cancers (TCs): Can this be gleaned from pathology reports? JOURNAL OF CLINICAL ONCOLOGY, 33(15).

Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., … Mittra, E. (2019). Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clinical Nuclear Medicine.

Application of pharmacoeconomics to formulary management in a health system setting
Studdert, A. L., Gong, C. L., Srinivas, S., Chin, A. L., & Deresinski, S. (2019). Application of pharmacoeconomics to formulary management in a health system setting. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 76(6), 381–86.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Martinez Chanza, N., Xie, W., Asim Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., … Harshman, L. C. (2019). Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. The Lancet. Oncology.

Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors
Kunder, C., Imae, Y., Srinivas, S., & Fan, A. C. (2018). Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.

Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma
Srinivas, S., Stein, D., Teltsch, D. Y., Tao, S., Cisar, L., & Ramaswamy, K. (2018). Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 24(8), 574–83.

Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
Yip, S. M., Wells, C., Moreira, R., Wong, A., Srinivas, S., Beuselinck, B., … Heng, D. Y. C. (2018). Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. CANCER, 124(18), 3677–83.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
Necchi, A., Pond, G. R., Smaldone, M. C., Pal, S. K., Chan, K., Wong, Y.-N., … Galsky, M. D. (2018). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European Urology Focus, 4(6), 937–45.

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma
Sonpavde, G. P., Mariani, L., Lo Vullo, S., Raggi, D., Giannatempo, P., Bamias, A., … Necchi, A. (2018). Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. JOURNAL OF UROLOGY, 200(6), 1207–14.

Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study
Necchi, A., Pond, G. R., Plimack, E. R., Niegisch, G., Yu, E. Y., Pal, S. K., … Galsky, M. D. (2018). Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. JOURNAL OF CLINICAL ONCOLOGY, 36(6).

New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.
Pond, G. R., Niegisch, G., Rosenberg, J. E., Dreicer, R., Powles, T., Necchi, A., … Sonpavde, G. (2018). New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. JOURNAL OF CLINICAL ONCOLOGY, 36(6).

Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.
Necchi, A., Mariani, L., Lo Vullo, S., Raggi, D., Giannatempo, P., Bamias, A., … Sonpavde, G. (2018). Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 36(6).

Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.
Xie, W., DiNatale, R., Hakimi, A. A., Donskov, F., Porta, C., Reaume, M. N., … Choueiri, T. K. (2018). Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy. JOURNAL OF CLINICAL ONCOLOGY, 36(6).

Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Stukalin, I., Wells, J. C., Graham, J., Yuasa, T., Beuselinck, B., Kollmannsberger, C. K., … Heng, D. Y. C. (2018). Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 36(6).

Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
Petrylak, D. P., Smith, D. C., Flaig, T. W., Zhang, J., Sridhar, S. S., Ruether, J. D., … Rosenberg, J. E. (2018). Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study. JOURNAL OF CLINICAL ONCOLOGY, 36(6).

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population
Necchi, A., Pond, G. R., Pal, S. K., Agarwal, N., Bowles, D. W., Plimack, E. R., … Galsky, M. D. (2018). Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. CLINICAL GENITOURINARY CANCER, 16(2), E483–E490.

Recommendations for the Management of Rare Kidney Cancers
Giles, R. H., Choueiri, T. K., Heng, D. Y., Albiges, L., Hsieh, J. J., Linehan, W. M., … Bex, A. (2017). Recommendations for the Management of Rare Kidney Cancers. EUROPEAN UROLOGY, 72(6), 974–83.

Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Yip, S., Wells, C., Moreira, R. B., Wong, A., Srinivas, S., Beuselinck, B., … Heng, D. Y. C. (2017). Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 35.

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma
Pal, S. K., Sonpavde, G., Agarwal, N., Vogelzang, N. J., Srinivas, S., Haas, N. B., … Choueiri, T. K. (2017). Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. EUROPEAN UROLOGY, 72(4), 557–64.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
Necchi, A., Mariani, L., Lo Vullo, S., Yu, E. Y., Woods, M. E., Wong, Y.-N., … Hendricksen, K. (2017). Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus.

Bone scan index as a new imaging biomarker in response assessment of prostate cancer patients with bone metastasis
Park, S., Srinivas, S., & Mittra, E. (2017). Bone scan index as a new imaging biomarker in response assessment of prostate cancer patients with bone metastasis. JOURNAL OF NUCLEAR MEDICINE, 58.

Automated bone scan index as a prognostic tool in prostate cancer patients with bone metastasis
Park, S., Srinivas, S., & Mittra, E. (2017). Automated bone scan index as a prognostic tool in prostate cancer patients with bone metastasis. JOURNAL OF NUCLEAR MEDICINE, 58.

Evaluation of FDG PET/CT measurement parameters for prediction of the prognosis after Sunitinib Therapy in Renal Cell Carcinoma
Minamimoto, R., Barkhodari, A., Harshman, L., Quon, A., & Srinivas, S. (2015). Evaluation of FDG PET/CT measurement parameters for prediction of the prognosis after Sunitinib Therapy in Renal Cell Carcinoma. JOURNAL OF NUCLEAR MEDICINE, 56(3).

Timing of angiotensin system inhibitor use and overall survival in patients on tyrosine kinase inhibitors for renal cell carcinoma
Lam, A. P., Allen, J., & Srinivas, S. (2014). Timing of angiotensin system inhibitor use and overall survival in patients on tyrosine kinase inhibitors for renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.
Srinivas, S., Narayanan, S., Harshman, L. C., Pachynski, R. K., Lam, A. P., Fan, A. C., … Vaishampayan, U. N. (2015). Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer. JOURNAL OF CLINICAL ONCOLOGY, 33(7).

First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
Harshman, L. C., Kroeger, N., Rha, S. Y., Donskov, F., Wood, L., Tantravahi, S. K., … Choueiri, T. K. (2013). First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC). JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC).
Srinivas, S., Narayanan, S., Harshman, L. C., Lam, A. P., Vaishampayan, U. N., Haas, D., … Pachynski, R. (2014). Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC). JOURNAL OF CLINICAL ONCOLOGY, 32(4).

Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).
Srinivasan, R., Bottaro, D. P., Choueiri, T. K., Vaishampayan, U. N., Rosenberg, J. E., Logan, T., … Linehan, W. M. (2012). Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). JOURNAL OF CLINICAL ONCOLOGY, 30(5).

A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.
Choueiri, T. K., Vaishampayan, U. N., Rosenberg, J. E., Logan, T., Harzstark, A. L., Rini, B. I., … Srinivasan, R. (2012). A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. JOURNAL OF CLINICAL ONCOLOGY, 30(5).

Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC
Fan, A. C., Leppert, J., Liliental, J. E., Xu, L., Thong, A. E., Yost, C., … Felsher, D. W. (2013). Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium
Harshman, L. C., Wood, L., Srinivas, S., Heng, D. Y. C., & Choueiri, T. K. (2013). First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium. JOURNAL OF CLINICAL ONCOLOGY, 31(6).

Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).
Grivas, P., Agarwal, N., Siefker-Radtke, A. O., Daignault, S., Puzanov, I., MacVicar, G. R., … Hussain, M. (2012). Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Formulating the Question and Objectives
Harshman, L. C., Srinivas, S., Symanowski, J. T., & Vogelzang, N. J. (2010). Formulating the Question and Objectives. ONCOLOGY CLINICAL TRIALS, 29–34.

Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
Escudier, B., Roigas, J., Gillessen, S., Srinivas, S., Pisa, P., Vogelzang, N., … De Mulder, P. (2006). Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC). ANNALS OF ONCOLOGY, 17, 144.

CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
Motzer, R. J., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., … Escudier, B. (2016). CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY, 34(2).

Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT).
Srinivas, S., Stein, D., Teltsch, D. Y., Tao, S., & Ramaswamy, K. (2016). Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT). JOURNAL OF CLINICAL ONCOLOGY, 34(2).

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
Motzer, R. J., Escudier, B., Mcdermott, D. F., George, S., Hammers, H. J., Srinivas, S., … Sharma, P. (2015). CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC). BJU INTERNATIONAL, 116, 17.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.
Bamias, A., Tzannis, K., Bamia, C., Harshman, L. C., Crabb, S., Plimack, E. R., … Galsky, M. D. (2019). The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. The Oncologist.

Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis.
Abogunrin, S., Ashaye, A. O., Cappelleri, J. C., Clair, A. G., Fahrbach, K., Ramaswamy, K., … Zanotti, G. (2019). Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis. Future Oncology (London, England).

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Changa, N. M., Xie, W., Bilen, M. A., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., … Harshman, L. C. (2019). Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. LANCET ONCOLOGY, 20(4), 581–90.

Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., … Mittra, E. (2019). Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. CLINICAL NUCLEAR MEDICINE, 44(4), E272–E279.

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).
Hahn, N. M., Powles, T., Massard, C., Arkenau, H.-T., Friedlander, T. W., Holmes, C. J., … O'Donnell, P. H. (2017). Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). JOURNAL OF CLINICAL ONCOLOGY, 35.

Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response.
Chen, V., Gong, C., Zhang, C. A., Srinivas, S., Lee, H. E., & Fan, A. C. (2017). Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response. JOURNAL OF CLINICAL ONCOLOGY, 35.

Prostate Cancer, Version 2.2019
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D'Amico, A., Davis, B. J., Dorff, T., … Freedman-Cass, D. A. (2019). Prostate Cancer, Version 2.2019. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(5), 479–505.

Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo (R) in mCRPC Patients
Song, H., Yohannan, T., Srinivas, S., Vasanawala, S., & Iagaru, A. (2018). Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo (R) in mCRPC Patients. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC.

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C., … Hahn, N. M. (2017). Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 35(6).

Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
Bosse, D., Xie, W., Wells, C., Lalani, A.-K. A., Donskov, F., Bent, A., … Heng, D. Y. C. (2017). Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). JOURNAL OF CLINICAL ONCOLOGY, 35.

Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma.
Chen, V. J., Hernandez-Meza, G., Agrawal, P., Zhang, C. A., Xie, L., Gong, C. L., … Fan, A. C. (2019). Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma. Cancers, 11(7).

Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
Balar, A. V., Galsky, M. D., Loriot, Y., Dawson, N. A., Necchi, A., Srinivas, S., … Bajorin, D. F. (2016). Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. JOURNAL OF CLINICAL ONCOLOGY, 34(18).

Second-line chemotherapy in older patients with metastatic urothelial carcinoma: Pooled analysis of 10 second-line studies.
Salah, S., Lee, J.-L., Rozzi, A., Lewin, J. H., Kitamura, H., Matsumoto, K., … Izumi, K. (2016). Second-line chemotherapy in older patients with metastatic urothelial carcinoma: Pooled analysis of 10 second-line studies. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).
Necchi, A., Sonpavde, G., Lo Vullo, S., Bamias, A., Crabb, S. J., Harshman, L. C., … Mariani, L. (2016). The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT). JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Platinum retreatment in second line chemotherapy for metastatic urothelial carcinoma (UC): Assessing the concept of platinum sensitivity and predictors of survival.
Ma'koseh, M., Kitamura, H., Srinivas, S., Lewin, J. H., & Salah, S. (2016). Platinum retreatment in second line chemotherapy for metastatic urothelial carcinoma (UC): Assessing the concept of platinum sensitivity and predictors of survival. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
Motzer, R. J., Sharma, P., Escudier, B. J., McDermott, D. F., George, S., Srinivas, S., … Hammers, H. J. (2016). Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC)
Wells, J. C., Donskov, F., Fraccon, A. P., Pasini, F., Bjarnason, G. A., Knox, J. J., … Heng, D. Y. C. (2016). Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Application of pharmacoeconomics to formulary management in a health system setting.
Studdert, A. L., Gong, C. L., Srinivas, S., Chin, A. L., & Deresinski, S. (2019). Application of pharmacoeconomics to formulary management in a health system setting. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists, 76(6), 381–386.

An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.
Harshman, L. C., Gray, K. P., Polacek, L., Taplin, M.-E., Choudhury, A. D., Pomerantz, M. M., … Sweeney, C. (2016). An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Prognostic factors for pancreatic metastases in renal cell cancer.
Chung, A., Li, S., Shah, S., Fan, A. C., & Srinivas, S. (2016). Prognostic factors for pancreatic metastases in renal cell cancer. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis
Abogunrin, S., Ashaye, A. O., Cappelleri, J. C., Clair, A. G., Fahrbach, K., Ramaswamy, K., … Zanotti, G. (2019). Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis. FUTURE ONCOLOGY, 15(18), 2175–90.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis
Necchi, A., Mariani, L., Lo Vullo, S., Yu, E. Y., Woods, M. E., Wong, Y.-N., … Hendricksen, K. (2019). Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. EUROPEAN UROLOGY FOCUS, 5(2), 242–49.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study
Necchi, A., Pond, G. R., Smaldone, M. C., Pal, S. K., Chan, K., Wong, Y.-N., … Galsky, M. D. (2018). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. EUROPEAN UROLOGY FOCUS, 4(6), 937–45.

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
Feldman, D. R., Hu, J. S., Patil, S., Reuter, V. E., Srinivas, S., Stadler, W. M., … Motzer, R. J. (2019). Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., … Simmons, S. J. (2019). Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC). JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.
Bhindi, B., Graham, J., Wells, C., Donskov, F., Pasini, F., Lee, J.-L., … Heng, D. Y. C. (2019). Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.
Sonpavde, G., Manitz, J., Gao, C., Hennessy, D., Makari, D., Niegisch, G., … Pond, G. R. (2019). 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
Grivas, P., Teo, M. Y., Vogelzang, N., Alva, A., Zakharia, Y., Adra, N., … Chowdhury, S. (2019). ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma. CANCER RESEARCH, 79(13).

Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.
Apolo, A. B., Rosenberg, J. E., Kim, W. Y., Chen, R. C., Sonpavde, G., Srinivas, S., … Morris, M. J. (2019). Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
Grivas, P., Vogelzang, N. J., Alva, A. S., Feyerabend, S., Loriot, Y., Necchi, A., … Chowdhury, S. (2019). ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC). JOURNAL OF CLINICAL ONCOLOGY, 37(7).

Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
Rosenberg, J. E., Sridhar, S. S., Zhang, J., Smith, D. C., Ruether, J. D., Flaig, T. W., … Petrylak, D. P. (2019). Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC). JOURNAL OF CLINICAL ONCOLOGY, 37(7).

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer
Bamias, A., Tzannis, K., Bamia, C., Harshman, L. C., Crabb, S., Plimack, E. R., … Galsky, M. D. (2019). The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. ONCOLOGIST, 24(10), 1348–55.

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg, J., Sridhar, S. S., Zhang, J., Smith, D., Ruether, D., Flaig, T. W., … Petrylak, D. P. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1902044.

Prostate Cancer Brain Metastases: A Single-Institution Experience.
Bhambhvani, H. P., Greenberg, D. R., Srinivas, S., & Gephart, M. H. (2020). Prostate Cancer Brain Metastases: A Single-Institution Experience. World Neurosurgery.

Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27).

Patient and caregiver benefit-risk preferences for non metastatic castration-resistant prostate cancer treatment (nmCRPC).
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., … Simmons, S. J. (2019). Patient and caregiver benefit-risk preferences for non metastatic castration-resistant prostate cancer treatment (nmCRPC). JOURNAL OF CLINICAL ONCOLOGY, 37(27).

Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi, B., Graham, J., Wells, J. C., Bakouny, Z., Donskov, F., Fraccon, A., … Heng, D. Y. (2020). Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology.

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M. I., Srinivas, S., Petrylak, D. P., … Hoimes, C. J. (2020). Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 38(6).

Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial
Grivas, P., Loriot, Y., Feyerabend, S., Morales-Barrera, R., Teo, M. Y., Vogelzang, N. J., … Chowdhury, S. (2020). Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial. JOURNAL OF CLINICAL ONCOLOGY, 38(6).

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)
Motzer, R. J., Tykodi, S. S., Escudier, B., Oudard, S., Hammers, H. J., McDermott, D. F., … Tannir, N. M. (2020). Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). JOURNAL OF CLINICAL ONCOLOGY, 38(6).

Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study
Agarwal, N., Loriot, Y., McGregor, B. A., Dreicer, R., Dorff, T. B., Maughan, B. L., … Pal, S. K. (2020). Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. JOURNAL OF CLINICAL ONCOLOGY, 38(6).

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde, G., Manitz, J., Gao, C., Tayama, D., Kaiser, C., Hennessy, D., … Pond, G. R. (2020). Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. The Journal of Urology, 101097JU0000000000001199.

Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., … Simmons, S. J. (2020). Physician preferences for non-metastatic castration-resistant prostate cancer treatment. BMC Urology, 20(1), 73.

Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.
Bhambhvani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., … Shah, J. B. (2020). Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer. Urologic Oncology.

Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality.
Karimi, Y., Divi, V., Srinivas, S., Smith, A. S., Hansen, J., Tokareva, I., … Blayney, D. W. (2019). Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
Srinivas, S., Mohamed, A. F., Appukkuttan, S., Botteman, M., Ng, X., Joshi, N., … Simmons, S. J. (2020). Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment. Cancer Medicine.

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., … Tannir, N. M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer.

Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma
Chen, V., Gong, C., Hoerner, C. R., Zhang, C. A., Srinivas, S., & Fan, A. C. (2018). Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
Rosenberg, J. E., Sridhar, S. S., Zhang, J., Smith, D. C., Ruether, J. D., Flaig, T. W., … Petrylak, D. P. (2018). Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC). JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Feldman, D. R., Hu, J., Srinivas, S., Stadler, W. M., Costello, B. A., Appleman, L. J., … Motzer, R. J. (2018). Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
Tripathi, A., Supko, J. G., Gray, K. P., Melnick, Z., Regan, M. M., Taplin, M.-E. E., … Harshman, L. C. (2020). Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B. L., … Iagaru, A. (2020). Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
Dudani, S., Gan, C. L., Wells, C., Bakouny, Z., Dizman, N., Pal, S. K., … Heng, D. Y. C. (2020). Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
Agarwal, N., Loriot, Y., McGregor, B. A., Dreicer, R., Dorff, T. B., Maughan, B. L., … Pal, S. K. (2020). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M., Srinivas, S., Petrylak, D. P., … Hoimes, C. J. (2020). Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

Recent Developments in the Management of Advanced Prostate Cancer
Srinivas, S. (2020). Recent Developments in the Management of Advanced Prostate Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 18(7), 969–72.

Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
Hirotsu, K. E., Rana, J., Wang, J. Y., Raghavan, S. S., Rieger, K. E., Srinivas, S., … Zaba, L. (2020). Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. Journal of the American Academy of Dermatology.

Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens.
Do, O. A., Ferris, L. A., Holt, S. K., Ramos, J. D., Harshman, L. C., Plimack, E. R., … Yu, E. Y. (2020). Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. Clinical Genitourinary Cancer.

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., … Freedman-Cass, D. A. (2021). NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(2), 134–43.

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Waliany, S., Sainani, K. L., Park, L. S., Zhang, C. A., Srinivas, S., & Witteles, R. M. (2019). Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC: CARDIOONCOLOGY, 1(1), 24–36.

Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
Mar, N., Friedlander, T. W., Hoimes, C. J., Flaig, T. W., Bilen, M. A., Balar, A. V., … Milowsky, M. (2020). Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era.
Parikh, D. A., Serrato, P. I., Srinivas, S., Ryckman, T. S., Salomon, J., & Goldhaber-Fiebert, J. D. (2020). Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.
Baratto, L., Song, H., Duan, H., Aparici, C. M., Davidzon, G., Moradi, F., … Iagaru, A. (2020). A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.
Do, O. A., Ferris, L., Holt, S. K., Ramos, J., Harshman, L. C., Plimack, E. R., … Yu, E. Y. (2020). Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine.

Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39.

Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.
Wong, R. L., Ferris, L., Do, O. A., Holt, S. K., Ramos, J., Crabb, S. J., … Yu, E. Y. (2021). Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Addressing financial toxicity in urologic oncology patients.
Parikh, D. A., Srinivas, S., Kerr, E., & Patel, M. (2021). Addressing financial toxicity in urologic oncology patients. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma after Previous Platinum-Based Chemotherapy for Metastatic Disease.
Wong, R. L., Ferris, L. A., Do, O. A., Holt, S. K., Ramos, J. D., Crabb, S. J., … Yu, E. Y. (2021). Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma after Previous Platinum-Based Chemotherapy for Metastatic Disease. The Oncologist.

Management of Metastatic Castration-Resistant Prostate Cancer
Srinivas, S. (2021). Management of Metastatic Castration-Resistant Prostate Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 19(5.5), 614–616.

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.
Waliany, S., Sainani, K. L., Park, L. S., Zhang, C. A., Srinivas, S., & Witteles, R. M. (2019). Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC. CardioOncology, 1(1), 24–36.

To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
Srinivas, S., & Iagaru, A. (2021). To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine.

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Pal, S. K., Frankel, P. H., Mortazavi, A., Milowsky, M., Vaishampayan, U., Parikh, M., … Lara, P. N. (2021). Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncology.

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal, S. K., McGregor, B., Suarez, C., Tsao, C.-K., Kelly, W., Vaishampayan, U., … Agarwal, N. (2021). Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2100939.

Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91.

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
Jadvar, H., Calais, J., Fanti, S., Feng, F., Greene, K. L., Gulley, J. L., … Hope, T. A. (2021). Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine.

Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
Stukalin, I., Wells, J. C., Fraccon, A., Pasini, F., Porta, C., Lalani, A.-K. A., … Heng, D. Y. C. (2018). Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). KIDNEY CANCER, 2(1), 31–36.

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
Friedlander, T. W., Milowsky, M. I., Bilen, M. A., Srinivas, S., Mckay, R. R., Flaig, T. W., … Rosenberg, J. E. (2021). Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
Pal, S. K., Mortazavi, A., Milowsky, M. I., Vaishampayan, U. N., Parikh, M., Lyou, Y., … Lara, P. (2021). A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Evolving oncology provider perspectives on care delivery during the COVID-19 pandemic.
Parikh, D. A., Ragavan, M. V., Srinivas, S., Garrigues, S., Rosenthal, E. L., & Patel, M. I. (2021). Evolving oncology provider perspectives on care delivery during the COVID-19 pandemic. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
Jadvar, H., Calais, J., Fanti, S., Feng, F., Greene, K. L., Gulley, J. L., … Hope, T. A. (2022). Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. JOURNAL OF NUCLEAR MEDICINE, 63(1), 59–68.

Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., … Khaki, A. R. (2022). Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T. S., Srinivas, S., Rosenberg, J. E., … Hoimes, C. J. (2022). Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).
Hoimes, C. J., Flaig, T. W., Srinivas, S., Mar, N., Petrylak, D. P., O'Donnell, P. H., … Rosenberg, J. E. (2022). Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal, N., McGregor, B., Maughan, B. L., Dorff, T. B., Kelly, W., Fang, B., … Pal, S. (2022). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). The Lancet. Oncology.

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730.

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., … Rosenberg, J. E. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 101200JCO2201643.

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.
Chiang, R. S., Glover, M. J., Khaki, A. R., & Srinivas, S. (2022). Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. OncoTargets and Therapy, 15, 1259–1269.

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.
Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T. S., Srinivas, S., Rosenberg, J. E., … Hoimes, C. J. (2022). Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128.

Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams.
Shore, N. D., Morgans, A. K., El-Haddad, G., Srinivas, S., & Abramowitz, M. (2022). Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams. Targeted Oncology.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., … Omlin, A. (2022). Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology.

In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
Molina, G. E., Schwartz, B., Srinivas, S., Shah, S., & Zaba, L. C. (2023). In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity. European Urology.

NCCN Guidelines Insights: Prostate Cancer, Version 1.2023.
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., … Freedman-Cass, D. A. (2022). NCCN Guidelines Insights: Prostate Cancer, Version 1.2023. Journal of the National Comprehensive Cancer Network : JNCCN, 20(12), 1288–1298.

Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei lagaru
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Nguyen, J., … Iagaru, A. (2022). Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei lagaru. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., … Omlin, A. (2023). Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer (Oxford, England : 1990), 185, 178–215.

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell, P. H., Milowsky, M. I., Petrylak, D. P., Hoimes, C. J., Flaig, T. W., Mar, N., … Rosenberg, J. E. (2023). Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2202887.

Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C.-S., Shah, S., … Khaki, A. R. (2023). Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
Flaig, T. W., Rosenberg, J. E., Hoimes, C. J., O'Donnell, P. H., Mar, N., Gourdin, T. S., … Petrylak, D. P. (2023). Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
Gupta, S., Rosenberg, J. E., Mckay, R. R., Flaig, T. W., Petrylak, D. P., Hoimes, C. J., … Milowsky, M. I. (2023). Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., … Freedman-Cass, D. A. (2023). Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 21(10), 1067–1096.

A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., … Rosenberg, J. E. (2023). A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. Future Oncology (London, England).

Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
Khaki, A. R., Fan, A. C., Shah, S., Parikh, D. A., Chien, J., Moore, K., … Srinivas, S. (2023). Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
Milowsky, M. I., O'Donnell, P. H., Hoimes, C. J., Petrylak, D. P., Flaig, T. W., Moon, H. H., … Rosenberg, J. E. (2023). Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.
O'Donnell, P. H., Rosenberg, J. E., Hoimes, C. J., Petrylak, D. P., Milowsky, M. I., Mckay, R. R., … Flaig, T. W. (2023). Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Milowsky, M. I., O'Donnell, P. H., Hoimes, C. J., Petrylak, D. P., Flaig, T. W., Moon, H. H., … Rosenberg, J. E. (2024). Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2301547.

Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program.
Parikh, D. A., Rodriguez, G. M., Ragavan, M., Kerr, E., Asuncion, M. K., Hansen, J., … Patel, M. I. (2024). Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 32(3), 161.

68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., … Iagaru, A. (2024). 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. The Lancet. Oncology.

Prostate Cancer, Version 3.2024.
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., … Freedman-Cass, D. A. (2024). Prostate Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network : JNCCN, 22(3), 140–150.

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., … Iagaru, A. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging.